芪苈强心胶囊与重组人脑利钠肽联合治疗扩张型心肌病心力衰竭的疗效分析(1)
[摘要] 目的 探討芪苈强心胶囊与重组人脑利钠肽联合治疗扩张型心肌病心力衰竭的临床效果。 方法 选取2015年10月～2018年1月我院收治的扩张型心肌病心力衰竭患者79例作为研究对象，随机分为研究组(n=40)与对照组(n=39)。在常规治疗的基础上，对照组给予重组人脑利钠肽治疗，研究组给予芪苈强心胶囊与重组人脑利钠肽联合治疗，比较两组临床疗效、治疗前后心功能。 结果 研究组治疗总有效率为95.00%，明显高于对照组的79.49%，差异有统计学意义(P<0.05)。治疗后两组LVEDd、LVESd均较治疗前降低，LVEF及6 min步行距离均较治疗前增加，且治疗后研究组LVEDd、LVESd低于对照组，LVEF及6 min步行距离高于对照组，差异有统计学意义(P<0.05)。 结论 芪苈强心胶囊与重组人脑利钠肽联合治疗扩张型心肌病心力衰竭效果更显著，总有效率更高，在改善心功能方面更有优势，更有利于提高患者生活质量。
[关键词] 扩张型心肌病;心力衰竭;芪苈强心胶囊;重组人脑利钠肽
[中图分类号] R541.6 [文献标识码] B [文章编号] 1673-9701(2019)34-0109-04
Analysis on the therapeutic effect of Qili Qiangxin capsule combined with recombinant human brain natriuretic peptide in the treatment of dilated cardiomyopathy complicated with heart failure
DONG Jian
Department of Cardiology， Xinmin People’s Hospital in Liaoning Province， Xinmin 110300， China
[Abstract] Objective To investigate the clinical effect of Qili Qiangxin capsule combined with recombinant human brain natriuretic peptide in the treatment of dilated cardiomyopathy complicated with heart failure. Methods A total of 79 patients with dilated cardiomyopathy complicated with heart failure who were admitted to our hospital from October 2015 to January 2018 were collected as study subjects. They were randomly divided into study group (n=40) and control group(n=39). On the basis of routine treatment， the control group was given recombinant human brain natriuretic peptide， and the study group was given Qili Qiangxin capsule combined with recombinant human brain natriuretic peptide. The clinical efficacy and cardiac function before and after treatment were compared between the two groups. Results The total effective rate in the study group was 95.00%， which was significantly higher than that in the control group (79.49%)， and the difference was statistically significant (P<0.05). After treatment， LVEDd and LVESd were lower than those before treatment in both groups， and LVEF and 6-min walking distance were increased compared with those before treatment. After treatment， the LVEDd and LVESd in the study group were lower than those in the control group， and the LVEP and 6-min walking distance were higher than those in the control group. The differences were statistically significant(P<0.05). Conclusion The combination of Qili Qiangxin capsule and recombinant human brain natriuretic peptide is more effective in the treatment of dilated cardiomyopathy complicated with heart failure， and the total effective rate is higher. It has more advantages in improving heart function and is more conducive to the improvement of patients' quality of life., http://www.100md.com(董建)
[关键词] 扩张型心肌病;心力衰竭;芪苈强心胶囊;重组人脑利钠肽
[中图分类号] R541.6 [文献标识码] B [文章编号] 1673-9701(2019)34-0109-04
Analysis on the therapeutic effect of Qili Qiangxin capsule combined with recombinant human brain natriuretic peptide in the treatment of dilated cardiomyopathy complicated with heart failure
DONG Jian
Department of Cardiology， Xinmin People’s Hospital in Liaoning Province， Xinmin 110300， China
[Abstract] Objective To investigate the clinical effect of Qili Qiangxin capsule combined with recombinant human brain natriuretic peptide in the treatment of dilated cardiomyopathy complicated with heart failure. Methods A total of 79 patients with dilated cardiomyopathy complicated with heart failure who were admitted to our hospital from October 2015 to January 2018 were collected as study subjects. They were randomly divided into study group (n=40) and control group(n=39). On the basis of routine treatment， the control group was given recombinant human brain natriuretic peptide， and the study group was given Qili Qiangxin capsule combined with recombinant human brain natriuretic peptide. The clinical efficacy and cardiac function before and after treatment were compared between the two groups. Results The total effective rate in the study group was 95.00%， which was significantly higher than that in the control group (79.49%)， and the difference was statistically significant (P<0.05). After treatment， LVEDd and LVESd were lower than those before treatment in both groups， and LVEF and 6-min walking distance were increased compared with those before treatment. After treatment， the LVEDd and LVESd in the study group were lower than those in the control group， and the LVEP and 6-min walking distance were higher than those in the control group. The differences were statistically significant(P<0.05). Conclusion The combination of Qili Qiangxin capsule and recombinant human brain natriuretic peptide is more effective in the treatment of dilated cardiomyopathy complicated with heart failure， and the total effective rate is higher. It has more advantages in improving heart function and is more conducive to the improvement of patients' quality of life., http://www.100md.com(董建)